Granted Patent
B2
US 12,268,658 · App. 17/789,631 · Granted Apr 8, 2025
Dosage regime with esketamine for treating major depressive disorder
Assignee:
CLEXIO BIOSCIENCES LTD.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides a method for safe and efficacious administration of esketamine.
Claims (19)
1. A method of treating major depressive disorder (MDD) in a human patient in need thereof with a once daily esketamine administration comprising orally administering to said patient, once every 24 hours, an immediate release oral dosage form comprising between about 41 mg and about 80 mg of esketamine over a treatment regimen of at least 28 days and wherein the esketamine C max of said administration is 30 ng/ml or less and/or the esketamine AUC 0-t of said administration is 60 ng*h/ml or less.
2. The method of claim 1 , wherein the oral dosage form comprises about 45 mg of esketamine.
3. The method of claim 1 , wherein the oral dosage form comprises about 50 mg of esketamine.
4. The method of claim 1 , wherein the oral dosage form comprises about 55 mg of esketamine.
5. The method of claim 1 , wherein the oral dosage form comprises about 60 mg of esketamine.
6. The method of claim 1 , wherein the oral dosage form comprises about 65 mg of esketamine.
7. The method of claim 1 , wherein the oral dosage form comprises about 70 mg of esketamine.
8. The method of claim 1 , wherein the oral dosage form comprises about 75 mg of esketamine.
9. The method of claim 1 , wherein the oral dosage form comprises about 80 mg of esketamine.
10. The method of claim 1 , wherein the treatment regimen is between 28 days and about 730 days.
11. The method of claim 10 , wherein the treatment regimen is between 28 days and about 365 days.
12. The method of claim 1 , wherein the treatment regimen results in a reduction of the symptoms of major depressive disorder (MDD) after at least 28 days of treatment.
13. The method of claim 1 , further comprising the administration of a second medication other than (R)-ketamine.
14. The method of claim 13 , wherein the second medication is an antidepressant, an antimanic agent, or an anxiolytic drug.
15. The method of claim 14 , wherein the antidepressant is selected from the group consisting of fluoxetine, sertraline, paroxetine, citalopram, escitalopram, venlafaxine, desvenlafaxine, duloxetine, and fluvoxamine.
16. The method of claim 1 , wherein the esketamine is esketamine hydrochloride.
17. The method of claim 1 , wherein the esketamine C max of said administration is 30 ng/ml or less.
18. The method of claim 1 , wherein the esketamine AUC 0-t of said administration is 60 ng*h/ml or less.
19. The method of claim 1 , wherein the esketamine C max of said administration is 30 ng/ml or less and the esketamine AUC 0-t of said administration is 60 ng*h/ml or less.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 28, 2022
From: SCHUMANN, JOHANNA; MIMROD, DORIT
To: CLEXIO BIOSCIENCES LTD.
Reel/Frame 060336/0975 →
Continuity (2)
Provisional Application
62954779
· Dec 30, 2019
References Cited (205)
US 7955619B2
· Shah et al.
· 2011
[cited by applicant]
US 9468611B2
· Manfredi et al.
· 2016
[cited by applicant]
US 20110160223A1
· Dingledine et al.
· 2011
[cited by applicant]
US 20130236573A1
· Singh et al.
· 2013
[cited by applicant]
US 20160067196A1
· Charney et al.
· 2016
[cited by applicant]
US 20160332962A1
· Chen et al.
· 2016
[cited by applicant]
US 20160338977A1
· Singh et al.
· 2016
[cited by applicant]
US 20180256534A1
· Erickson
· 2018
[cited by applicant]
CN 101466364A
· 2009
[cited by applicant]
CN 107735081A
· 2018
[cited by applicant]
DE 2062620A1
· 1971
[cited by applicant]
DE 102007009888A1
· 2008
[cited by applicant]
GB 1330878A
· 1973
[cited by applicant]
JP 2018515557A
· 2018
[cited by applicant]
WO 2007111880A2
· 2007
[cited by applicant]
WO 2008023261A1
· 2008
[cited by applicant]
WO 2008033523A1
· 2008
[cited by applicant]
WO 2011020061A2
· 2011
[cited by applicant]
WO 2013138322A1
· 2013
[cited by applicant]
WO 2014006004A1
· 2014
[cited by applicant]
WO 2014020155A1
· 2014
[cited by applicant]
WO 2015031410A1
· 2015
[cited by applicant]
WO 2015051259A1
· 2015
[cited by applicant]
WO 2015066172A1
· 2015
[cited by applicant]
WO 2015158854A1
· 2015
[cited by applicant]
WO 2016044150A1
· 2016
[cited by applicant]
WO 2016073653A1
· 2016
[cited by applicant]
WO 2016094358A1
· 2016
[cited by applicant]
WO 2016187491A1
· 2016
[cited by applicant]
WO 2017041112A1
· 2017
[cited by applicant]
WO 2018079693A1
· 2018
[cited by applicant]
WO 2018102488A1
· 2018
[cited by applicant]
WO 2018234568A2
· 2018
[cited by applicant]
WO 2019073408A1
· 2019
[cited by applicant]
WO 2019126108A1
· 2019
[cited by applicant]
WO 2020003195A1
· 2020
[cited by applicant]
WO 2020225773A1
· 2020
[cited by applicant]
WO 2021026232A1
· 2021
[cited by applicant]
WO 2021116498A1
· 2021
[cited by applicant]
Co-pending U.S. Appl. No. 18/193,122, filed Mar. 30, 2023.
[cited by applicant]
Co-pending U.S. Appl. No. 18/193,083, filed Mar. 30, 2023.
[cited by applicant]
Cusin et al. Rating Scales for Depression, Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health, L. Baer, M.A. Blais (Eds.), Humana Press, 2010, Chapter 2, pp. 7-35.
[cited by applicant]
Peltoniemi et al., “Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy”, Clin Pharmacokinet 2016, 55, 1059-1077.
[cited by applicant]
Ostuzzi et al., “Cochrane Database of Systematic Reviews, Antidepressants for the treatment of depression in people with cancer (Review)”, 2018, 1-78.
[cited by applicant]
Oye et al., “Effects of Ketamine on Sensory Perception: Evidence for a Role of N-Methyl-D-Aspartate Receptors”, Journal of Pharmacology and Experimental Therapeutics, Mar. 1992, 260(3), 1209-1213.
[cited by applicant]
Papakostas et al., “Cognitive Impairment after Small-dose Ketamine Isomers in Comparison to Equianalgesic Racemic Ketamine in Human Volunteers”, American Society of Anesthesiologists, Feb. 2002, vol. 96, No. 2, pp. 357-…
[cited by applicant]
Papakostas et al., “The Nature of Placebo Response in Clinical Studies of Major Depressive Disorder”, J. Clin. Psychiatry 76:4, 456, Apr. 2015.
[cited by applicant]
Paslakis et al., “Oral Administration of the NMDA Receptor Antagonist S-Ketamine as Add-On Therapy of Depression: A Case Series”, Pharmacopsychiatry, Jan. 2010, 43(1), 33-35.
[cited by applicant]
Patent and Exclusivity for: N211243, Product 001, Esketamine Hydrochloride (Spravato) Spray EQ 28mg BASE, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, [Retrieved from internet on Apr. 4,…
[cited by applicant]
Peltoniemi et al., “Rifampicin has a Profound Effect on the Pharmacokinetics of Oral S-Ketamine and Less on Intravenous S-Ketamine”, Basic & Clinical Pharmacology, 2012, 111, 325-332.
[cited by applicant]
Peltoniemi et al., “S-ketamine concentrations are greatly increased by grapefruit juice,” European Journal of Clinical Pharmacology, vol. 68, No. 6, Jan. 2012, pp. 979-986.
[cited by applicant]
Pfenniger et al.; “Cognitive Impairment after Small-dose Ketamine Isomers in Comparison to Equianalgesic Racemic Ketamine in Human Volunteers”; Anesthesiology; vol. 96; 2002; p. 357-366.
[cited by applicant]
Pfenninger et al., “Cognitive Impairment after Small-dose Ketamine Isomers in Comparison to Equianalgesic Racemic Ketamine in Human Volunteers”, Anesthesiology, 2002, vol. 96, pp. 357-366.
[cited by applicant]
Preskorn et al: “Randomized Proof of Concept Trial of GLYX-13, an N-Methyl-D-Aspartate Receptor Glycine Site Partial Agonist, in Major Depressive Disorder Nonresponsive to a Previous Antidepressant Agent”, Journal of Ps…
[cited by applicant]
Reagan-Shaw, et al., Dose translation from animal to human studies revisited, The FASEB Journal, vol. 22, 2007, pp. 659-661.
[cited by applicant]
Rong et al ‘Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder’ Int. J. Environ. Res. Public Health 2018, 15, 771.
[cited by applicant]
Rot et al., “Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression”, Biol Psychiatry, 2010, 67, 139-145.
[cited by applicant]
Sanacora, G. et al., A Consensus Statement on the Use of Ketamine in the Treatment ofMood Disorders, JAMA Psychiatry, Apr. 2017, vol. 74, No. 4, 399-405.
[cited by applicant]
Schoevers et al., “Oral Ketamine for the Treatment of Pain and Treatment-Resistant Depression”,, British Journal of Psychiatry, 2016, 208, 108-113.
[cited by applicant]
Segmiller, et al, Repeated S-ketamine Infusions in Therapy Resistant Depression: A Case Series; American College of Clinical Pharmacology, vol. 53, Issue 9, Sep. 2013, pp. 996-998 (5pages).
[cited by applicant]
Shirawi, et al., Journal of Clinical Psychopharmacology, Oral Ketamine in Treatment-Resistant Depression, vol. 37, No. 4, Aug. 2017, pp. 1-4, 464-467.
[cited by applicant]
Shiroma et al., “Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression”, Journal of Affective Disorders, 155, 2014, 123-129.
[cited by applicant]
Singh et al., “Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study”, Biological Psychiatry, 2016, 80, 424-431.
[cited by applicant]
Smith-Apeldoorn et al: BMC Psychiatry; “Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial”, BMC Psychiatry, vol. 19:375, No. 1, Nov. 29, 2019; XPO55651157; pp. 1-9.
[cited by applicant]
Snaith et al., “The hospital anxiety and depression scale”, Feb. 1, 1986, vol. 292, 6516, p. 344.
[cited by applicant]
Sofia et al., “Evaluation of Ketamine HCI for Anti-Depressant Activity”, Arch. Int. Pharmacodyn. Ther., Mar. 1975, 214(1), 68-74.
[cited by applicant]
Spravato esketamine nasal spray, Approved Product Monograph, Canada, May 19, 2020, 1-59.
[cited by applicant]
Spravato Prescribing Information, Section 2.2, Mar. 2019.
[cited by applicant]
Thomas et al ‘Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness’ J Psychopharmacol…
[cited by applicant]
Toyama et al., “Genotoxic Effects of N-nitrosoketamine and Ketamine as Assessed by In Vitro Micronucleus Test in Chinese Hamster Lung Fibroblast Cell Line”, Environ. Health Prev. Med., May 2006, 11, 120-127.
[cited by applicant]
Vallesenor et al ‘A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks’ Br J Pharmacology (2014) 1…
[cited by applicant]
Van de Loo, et al., Psychopharmacology, The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study, (2017) 234: 3175-3183.
[cited by applicant]
Vesierra Label, Jan. 2018, 12 pages.
[cited by applicant]
Wallace et al: Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of I-4-chlorokynurenine in healthy volunteer, Scandinavian…
[cited by applicant]
White et al., “Comparative Pharmacology of the Ketamine Isomers”, Brit. Journal Anaesth., 1985, 57, 197-203.
[cited by applicant]
White, et al., “Pharmacology of Ketamine Isomers in Surgical Patients”, Anesthesiology, 1980, 52, 231-239.
[cited by applicant]
Witkin Jeffrey M et al: “Rapid-Acting Antidepressants”, Current Pharmaceutical Design, vol. 24, No. 22, Jun. 27, 2018 (Jun. 27, 2018), pp. 2556-2563.
[cited by applicant]
Yanagihara et al., “Plasma Concentration Profiles of Ketamine and Norketamine After Administration of Various Ketamine Preparations to Healthy Japanese Volunteers”, Biopharmaceutics & Drug Disposition, 2003, 24(1), 37-4…
[cited by applicant]
Yang et al., “R-ketamine: A Rapid-Onset and Sustained Antidepressant Without Psychotomimetic Side Effects”, Transl. Psychiatry, Sep. 2015, 11 pages.
[cited by applicant]
Zanos Panos, et al: “Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms”, Pharmacological Reviews, vol. 70, No. 3, Jun. 26, 2018 (Jun. 26, 2018), pp. 621-660.
[cited by applicant]
Zarate et al Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-on Trial1 Biol Psychiatry. Jun. 1, 2012; 71(11):939-946.
[cited by applicant]
Zhang et al., “R(-)-ketamine Shows Greater Potency and Longer Lasting Antidepressant Effects Than S (+)-ketamine” Pharmacology, Biochemistry and Behavior, Jan. 2014, 116, 137-141.
[cited by applicant]
Zhao et al., Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression, BJCP, 74:2, 2012, 304-314.
[cited by applicant]
Zigmond et al., “The Hospital Anxiety and Depression Scale”, 1983, 67, 361-370.
[cited by applicant]
Zulresso FDA Label, Full Prescribing Information, Sep. 30, 2019, 21 pages.
[cited by applicant]
Han et al: “Oral scopolamine augmentation for major depression”, Expert Rev. Neurother, 2013, 13(1), 19-21.
[cited by applicant]
Hartberg, et al., Psychopharmacology, Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study, 2018, (393-398), 6 pages.
[cited by applicant]
Hartvig et al., “Central Nervous System Effects of Subdissociative Doses of (S)-ketamine are Related to Plasma and Brain Concentrations Measured with Positron Emission Tomography in Healthy Volunteers”, Clin. Pharm. & T…
[cited by applicant]
Hashimoto et al., “R-ketamine: A Rapid-Onset and Sustained Antidepressant Without Risk of Brain Toxicity”, Psychological Medicine, Aug. 2016, 46, 2449-2451.
[cited by applicant]
Hasin et al., “Epidemiology of Major Depressive Disorder”, Arch. Gen. Psychiatry, 2005, 62, 1097-1106.
[cited by applicant]
Himmelseher et al., “Ketamine for Perioperative Pain Management”, Anesthesiology, Jan. 2005, vol. 102, 211-220.
[cited by applicant]
Huge et al., “Effects of low-dose intranasal (S)-ketamine in patients with Neuropathic pain”, European Journal of Pain, 2010, 387-394.
[cited by applicant]
Ihmsen et al, “Stereoselective pharmacokinetics of ketamine: R(-)-Ketamine inhibits the elimination of S(+)-ketamine”, Clinical Pharmacology & Therapeutics (2001) 70, 431-438.
[cited by applicant]
Irwin et al., “Daily Oral Ketamine for the Treatment of Depression and Anxiety in Patients Receiving Hospice Care: A 28-Day Open-Label Proof-of-Concept Trail”, Journal of Palliative Medicine, 2013, vol. 16, No. 8, 958-9…
[cited by applicant]
Jafarinia, et al., Journal of Affective Disorders, Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial 2…
[cited by applicant]
Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression, Innovation, Sep. 21, 2018, 6 pages.
[cited by applicant]
Janssen Study for NCT03808259, A Study to Investigate the Different Modes of (S) Ketamine Administration in Healthy Participants, Last Updated Sep. 12, 2019.
[cited by applicant]
Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression, Sep. 4, 2018 [Retrieved from internet https://www.prnewswire.com/news-releases/janssen-submits-esketamine-nasal…
[cited by applicant]
Jarventausta et al., “S-ketamine for the Treatment of Depression”, Psychiatria Fennica, 2015, 46, 11-20.
[cited by applicant]
Kelley et al., “Open-Label Placebo for Major Depressive Disorder: A Pilot Randomized Controlled Trial”, Psychother Psychosom 2012; 81(5), 1-4.
[cited by applicant]
Kelley et al., “Open-Label Placebo for Major Depressive Disorder: A Pilot Randomized Controlled Trial,” Psychotherapy and Psychosomatics, vol. 81, No. 5, Aug. 2012, pp. 312-314.
[cited by applicant]
Ketamine INN, Update Review Report Agenda Item 6.1, Expert Committee on Drug Dependence, WHO, 37th Meeting, Geneva, Nov. 2015, 46 pgs.
[cited by applicant]
Kharasch et al,. “Metabolism of Ketamine Stereoisomers by Human Liver Microsomes”, Anesthesiology, 1992, 77, 1201-1207.
[cited by applicant]
Kishimoto et al., Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA, Arch Osteoporos, 2015, 10:27.
[cited by applicant]
Kraus et al ‘Administration of ketamine for unipolar and bipolar depression’ Int J Psychiatry Clin Pract. Mar. 2017;21(I):2-12.
[cited by applicant]
Lara et al ‘Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression’ International Journal of Neuropsychopharmacology (2013), 16, 2111…
[cited by applicant]
Loebel et al ‘Lurasidone Monotherapy in the Treatment of Bipolar 1 Depression: A Randomized, Double-Blind, Placebo-Controlled Study’ Am J Psychiatry 2014; 171:160-168.
[cited by applicant]
Ionescu et al ‘A single infusion of ketamine improves depression scores in patients with anxious bipolar depression’ Bipolar Disord. Jun. 2015; 17(4): 438-443.
[cited by applicant]
Major Depressive Disorder: Developing Drugs for Treatment Guidance for Industry; U.S. Dept. of Health and Human Services Food and Drug Administration;—Center for Drug Evaluation and Research; Revision 1; Jun. 2018; 11 p…
[cited by applicant]
Malinosky et al., “Ketamine and Norketamine Plasma Concentrations after i.v., Nasal and Rectal Administration in Children”, British Journal of Anaesthesia, 1996, 22, 203-207.
[cited by applicant]
Marcus, S.C. et al., Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge, JMCP, Sep. 2015, vol. 21, No. 9, p. …
[cited by applicant]
Mathew et al., “Ketamine for Treatment-Resistant Unipolar Depression: Current Evidence”, CNS Drugs, Mar. 1, 2012, 26(3), 189-204.
[cited by applicant]
Molero et al., “Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review”, CNS Drugs, May 2018, 10 pages.
[cited by applicant]
Morrison, “Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study”, Psychopharmacology, Feb. 1, 2018, vol. 235, pp. 1107-1119.
[cited by applicant]
Mrazek et al., “A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996-2013”, Psychiatric Services, Aug. 2014, vol. 65, No. 8, 977-987.
[cited by applicant]
NCT01998958, Oct. 29, 2015.
[cited by applicant]
NCT02133001, Mar. 18, 2016.
[cited by applicant]
NCT02343289, Jan. 21, 2015.
[cited by applicant]
NCT02417064, Apr. 10, 2015.
[cited by applicant]
NCT02418585, Apr. 13, 2015.
[cited by applicant]
NCT02422186, Apr. 16, 2015.
[cited by applicant]
NCT02493868, Jul. 7, 2015.
[cited by applicant]
NCT02497287, Jun. 10, 2015.
[cited by applicant]
NCT02782104, May 25, 2016.
[cited by applicant]
NCT02918318, Sep. 27, 2016.
[cited by applicant]
NCT03039192, Feb. 1, 2017.
[cited by applicant]
NCT03097133, Mar. 27, 2017.
[cited by applicant]
NCT03185819, Jun. 12, 2017.
[cited by applicant]
NCT03434041, Feb. 18, 2018.
[cited by applicant]
NCT03965871 trial protocol as accessed Jul. 25, 2019.
[cited by applicant]
Netherlands Pharmacovigilance Centre report, Esketamine and hepatotoxicity, May 2013, 7 pages.
[cited by applicant]
Noppers et al., “Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: A report of 3 cases”., Pain, 152, 2011, 2179-2178.
[cited by applicant]
Nugent et al ‘Neural correlates of rapid antidepressant response to ketamine in bipolar disorder’ Bipolar Disord. Mar. 2014 ; 16(2): 119-128.
[cited by applicant]
Och-Ross et al., “Efficacy and Safety of Intranasal Esketamine Plus and Oral Antidepressant in Elderly Patients with Treatment-Resistant Depression”, 2018 Annual Meeting of the American Psychiatric Association (APA), Ma…
[cited by applicant]
“OxyContin® (oxycodone hydrochloride controlled-release) Tablets, for oral use, CII,” Highlights of Prescribing Information, Reference ID: 3155030, Jul. 2012, pp. 1-31.
[cited by applicant]
2019 FDA Esketamine Briefing Document, Esketamine Nasal Spray for Patients with Treatment-resistant Depression, Janssen Research & Development, LLC, Feb. 8, 2019, 1-260.
[cited by applicant]
Adhvaryu et al., “Genotoxic Effects of Ketamine on CHO Cells”, Arch. Toxicology, 1986, vol. 59, pp. 124-125.
[cited by applicant]
Alberich et al ‘Efficacy and safety of ketamine in bipolar depression : A systematic review’ Rev Psiquiatr Salud Ment (Bare.), May 2017; vol. 10(2), pp. 104-112.
[cited by applicant]
Allergan Study for NCT03726658, AGN-241751 in the Treatment of Major Depressive Disorder, Last Updated on Oct. 8, 2019.
[cited by applicant]
Angst et al, Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET), European Neuropsychopharmacology 7…
[cited by applicant]
Anonymous: “Trial NL6030 (NTR6161) Ketaminestudie”, Netherlands Trial register Oct. 21, 2016 (Oct. 21, 2016), pp. 1-6, XP002796356, Retrieved from the Internet: URL:https://www.trialregister.nl/trial/6030.
[cited by applicant]
APA Annual Meeting Poster P7-065, Mar. 18, 2018.
[cited by applicant]
APA Annual Meeting Poster P8-054, Mar. 18, 2018.
[cited by applicant]
Arabzadeh, et al., Journal of Affective Disorders, Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial, Journal of Affective Dis…
[cited by applicant]
ASCP Annual Meeting Poster T67, May 29, 2018.
[cited by applicant]
ASCP Annual Meeting Poster W68, May 29, 2018.
[cited by applicant]
Avinza® (morphine sulfate) extended-release capsules, for oral use, CII, Highlights of Prescribing Information, Reference ID: 3155722, Jul. 2012, pp. 1-18.
[cited by applicant]
Banwani et al ‘Ketamine-induced affective switch in a patient with treatment-resistant depression’ Indian J Pharmacol. Jul.Aug. 2015; 47(4): 454-455.
[cited by applicant]
Berman et al., “Antidepressant Effects of Ketamine in Depressed Patients”, Biol. Psychiatry, 2000, 351-354.
[cited by applicant]
Blonk et al., “Use of Oral Ketamine in Chronic Pain Management: A Review”, European Journal of Pain, 2010, 466-472.
[cited by applicant]
Bobo et al ‘Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice’ Depression and Anxiety 33:698-710 (2016).
[cited by applicant]
Body Weight at www.cnn.com/2018/12/20/health/us-average-height-weight-report/index.html (retrieved from the internet Aug. 25, 2021) (Year: 2018).
[cited by applicant]
Branerjee et al, “AGN-241751, an Orally Bioavailable Positive NMDA Receptor Modulator, Exhibits Rapid and Sustained Antidepressant-Like Effects in Rodents”, Biological Psychiatry, May 15, 2019, vol. 85, S348.
[cited by applicant]
Calabrese et al ‘A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar 1 or II Depression’ Am J Psychiatry 2005; 162:1351-1360.
[cited by applicant]
Canuso et al., “Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Con…
[cited by applicant]
Celon Pharma Press Release, Celon Pharma S.A. begins a clinical programme for Esketamine in the treatment of drug-resistant depression, Nov. 28, 2017.
[cited by applicant]
Celon Pharma Press Release, Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial; Jan. 5, 2018.
[cited by applicant]
Chen et al, “Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder”, European Neuropsychopharmacology, Sep. 2014, vol. 24, pp. 1753-1759.
[cited by applicant]
Chong et al., “Development of a Sublingual/Oral Formulation of Ketamine for Use in Neuropathic Pain”, Clin Drug Invest 2009; 29 (5): 317-324.
[cited by applicant]
Clements et al., “Bioavailability, Pharmacokinetics and Analgesic Activity of Ketamine in Humans”, Journal of Pharmaceutical Sciences, May 1982, 539-542.
[cited by applicant]
Correia-Melo et al ‘Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review’ Neuropsychiatric Disease and Treatment 2017:13 1627-1632.
[cited by applicant]
Cortef Product Label, Nov. 1993, 2 pages.
[cited by applicant]
Dahan et al., “Population pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief of chronic pain”, European Journal of Pain 15, 2011, 258-267.
[cited by applicant]
Daly et al., “A Randomized Withdrawal, Double-Blind, Multicenter Study of Esketamine Nasal Spray Plus an Oral Antidepressant for Relapse Prevention in Treatment-Resistant Depression”, Presented at the 2018 Annual Meetin…
[cited by applicant]
Daly et al., “Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial,” JAMA Psychiatry, 2018, vol. 75, No. 2, pp. 139-148.
[cited by applicant]
Daly et al.; Neuropsychopharmacology; Intranasal Esketamine in Treatment-resistant Depression, a Dose Response Study—Double Blind and Open Label Extension Data; (2015) 40, 5272-5442.
[cited by applicant]
Diazgranados et al ‘A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression’ Arch Gen Psychiatry. Aug. 2010; 67(8) 793-802.
[cited by applicant]
Domino, “Taming the Ketamine Tiger”, Anesthesiology, 2010, 113, 678-686.
[cited by applicant]
Durgam et al ‘An 8-Week Randomized, Double-Blind , Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar 1 Depression’ Am J Psychiatry 2016; 173:271-281.
[cited by applicant]
Earley et al ‘Cariprazine Treatment of Bipolar Depression :A Randomized Double-Blind Placebo-Controlled Phase 3 Study’ Am J Psychiatry Jun. 1, 2019;176(6):439-448.
[cited by applicant]
Ebert et al., “Norketamine, The Main Metabolite of Ketamine, is a non-competitive NMDA Receptor Antagonist in the Rat Cortex and Spinal Cord”, European Journal of Pharmacology, 1997, 333, 99-104.
[cited by applicant]
EMCDDA, Report on the Risk Assessment of Ketamine in the Framework of the Joint Action on New Synthetic Drugs, 2002, 120 pages.
[cited by applicant]
European Monitoring Centre for Drug and Drug Addition's 2002 risk assessment report of Ketamine, p. 49-50.
[cited by applicant]
Fanta et al., “Population Pharmacokinetics of S-ketamine and Norketamine in Healthy Volunteers After Intravenous and Oral Dosing”, Eur. J. Clin. Pharmacol., 2015, 441-447.
[cited by applicant]
Fanta et al., “Population Pharmacokinetics of S-ketamine and Norketamine in Healthy Volunteers After Intravenous and Oral Dosing”, Eur. J. Clin. Pharmacol., Mar. 1, 2015, vol. 71, No. 4, pp. 441-447.
[cited by applicant]
Fava et al: “Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial”, Am. J. Psychiatry, May 2016, 173, 49…
[cited by applicant]
Fava, et al., “Major Depressive Disorder”, Neuron, Nov. 2000, vol. 28, 335-341.
[cited by applicant]
Fond et al Ketamine's effectiveness in unipolar versus bipolar depression1 Psychopharmacology (2014) 231:4417-4418.
[cited by applicant]
Geisslinger et al., “Pharmacokinetics and Pharmacodynamics of Ketamine Enantiomers in Surgical Patients Using a Stereoselective Analytical Method”, British Journal of Anesthesia, 1993, 70, 666-671.
[cited by applicant]
Giorgetti, et al., “Effects of ketamine on psychomotor, sensory and cognitive functions relevant for driving ability”, Forensic Science International, 2015, vol. 252, pp. 127-142.
[cited by applicant]
Grady et al1 Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature1 Ment Health Clin [Internet], 2017;7(I):16-23.
[cited by applicant]
Grant et al., “Pharmacokinetics and Analgesic Effects of I.M. and Oral Ketamine”, British Journal of Anesthesia, 1981, 53, 805-810.
[cited by applicant]
Hagelberg et al., “Clarithromycin, a potent inhibitor of CYP3A, Greatly Increases Exposure to Oral S-ketamine”, European Journal of Pain, 2010, 625-629.
[cited by applicant]
“Vesierra 5 mg/ml solution for injection/infusion”, Summary of product characteristics, Feb. 1, 2018, pp. 12.
[cited by applicant]
Andrade, “Sustained-release, extended-release, and other time-release formulations in neuropsychiatry”, J Clin Psychiatry, Aug. 2015, vol. 76, No. 8, e995-e999.
[cited by applicant]
Dhillon et al., “Dosage regimens”, Chapter 22, Aulton's Pharmaceutics the Design and Manufacture of Medicines, Fifth Edition, edited by Aulton et al., 2018, pp. 24.
[cited by applicant]
Exhibit A, “Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs”, European Monitoring Centre for Drugs and Drug Addiction, 2002, pp. 121.
[cited by applicant]
Exhibit B, “Pharmacology/toxicology review and evaluation, Spravato (esketamine)”, Center for drug evaluation and research, Application No. 211243Orig1s000, Sep. 4, 2018, pp. 76.
[cited by applicant]
Exhibit C, “Assessment report Spravato”, Procedure No. EMEA/H/C/004535/0000, Nov. 21, 2019, European Medicines Agency, pp. 176.
[cited by applicant]
Exhibit D, “Guidance for Industry S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use”, Jun. 2012, pp. 36.
[cited by applicant]
McConnell et al., “Modified-release oral drug delivery”, Chapter 31, Modified-release oral drug delivery, Aulton's Pharmaceutics the Design and Manufacture of Medicines, Fifth Edition, Edited by Aulton et al., 2018, pp.…
[cited by applicant]
Peltoniemi et al., “Exposure to Oral S-ketamine Is Unaffected by Itraconazole but Greatly Increased by Ticlopidine”, Clin Pharmacol Ther., Vo. 90, No. 2, Aug. 2011, pp. 296-302.
[cited by applicant]
Sharpe et al., “Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs”, British Journal of Cancer, 2004, vol. 90, pp. 314-320.
[cited by applicant]
Wasteson et al., “Depression assessment and classification in palliative cancer patients: a systematic literature review”, Palliative Medicine, 2009, vol. 23, No. 8, pp. 739-753.
[cited by applicant]
Atsushi Hakura, “Genotoxicity Testing”, Folia Pharmacol. Jpn., vol. 130, 2007, 57-61.
[cited by applicant]
Cited By (1)